I am an analytical chemist and I received my training at Purdue University, a leading institution in analytical chemistry, especially in the field of mass spectrometry. I received my Ph.D. from Dr. Fred Regnier one of the founders of the field of bio-separation. While at Purdue I mainly focused on technology development in separation and mass spectrometry areas. These technologies were developed to address important issues in the field of proteomics such as post-translational modification enrichment and detection as well as improvement of mass spectral detection limits.
In 2007 I joined Prof. Ruedi Aebersold's laboratory, one of the leading proteomics lab in the world, at Institute for Systems Biology in Seattle where I was trained in high throughput quantitative proteomics and complementary systems biology technologies. During my postdoctoral research at ISB, I was involved in the development of Selected Reaction Monitoring (SRM), a newly adopted mass spectrometry technique that promises to revolutionize proteomics into an automated, accurate and reproducible data acquisition platform. This technology does not require the often limiting step of precursor ion selection for peptide ion fragmentation, but instead uses mass analyzers to monitor predefined peptide and fragment ion pairs. I have also spent significant amount of time and effort for platform standardization and inter-laboratory transferability which from the beginning affected proteomics credibility.
I received my Ph.D. in Chemistry from the University of California-Berkeley in 2005. My research in Evan Williams' lab involved using FT-ICR mass spectrometry and molecular modeling to study how interactions with metal ions and water molecules affected the structure of amino acids. After graduating I spent almost two years at a GMP contract lab in Madison, WI, where I was involved in many projects involving high-resolution LC/MS analysis of proteins and peptides. Following this I worked for nearly five years in the High-Throughput Analytical Chemistry group in the Chemical Biology and Therapeutics department at St. Jude Children's Research Hospital. While there I provided mass spectrometry support for many groups and was involved a number of projects in which I used selected reaction monitoring (SRM) for quantitation of small molecules in cell lines and animal tissues.
My focus here in the Proteomics Core Facility is targeted proteomics, where I will be using SRM for quantitation of specific proteins of interest. I am looking forward to many exciting collaborations!
I received my PhD (Biochemistry) from University of Hyderabad, India under the guidance of Prof.N Siva Kumar. After, successfully completing my PhD on "Functional characterization of Mannose 6-phospahate receptor proteins", I joined as a postdoctoral fellow for about 8 months in the laboratory of Dr.Shivaji, Center for Cellular and Molecular Biology (CCMB), India. My first postdoctoral project was focused on understanding the "Biological effects of microgravity on microorganisms using genomics and proteomics approaches". Later in 2009, I was offered a Post-Doctoral position from Dr.Usha Kasid lab at Lombardi Cancer Canter, Georgetown University Medical center, Washington DC. The project I worked on was "Transcriptional regulation of pro-apoptotic gene BLID and chemo sensitization of breast cancer cells to chemotherapeutic drugs".
My research experience involves in wide range of projects in protein biochemistry and cancer biology. Every project I do is a challenge and I take pleasure in taking these challenges. Every day is a learning experience for me and I strive and work hard to achieve what I want. I was inspired and encouraged by lot of people during 4 years of my research experience especially my Ph.D. mentor Dr.Nadimpalli Siva Kumar. It's my great pleasure to join Dr.Hamid Mirzaei's group at the Department of Biochemistry. I am very eagerly waiting to start my new projects; hopefully my effort can contribute in identifying novel biomarkers of Ubiquitinome in cancer biology.
I am a protein biochemist. For the past 13 years, I have been actively involved in developing various fluorescence-based technologies to understand how oxidative stress impairs protein homeostasis and contributes to aging and age-related diseases. Most importantly, these techniques can be useful analytical tool for functional proteomics to identify the proteins which undergo misfolding and aggregation in patho-physiological conditions. Most importantly, the subtle changes in oxidation level in protein (e.g., cysteine oxidation, protein carbonylation) can have effects on protein conformation which might have important role in various pathological conditions. Application of one of the assays particularly monitoring protein conformation in various neurodegenerative diseases would be robust because it can be used as high-throughput tool to quantify structure/function relationship of proteins
My name is Indhumathy Subramaniyan, a researcher with 6 years of experience in Bio-Technology. I joined UT Southwestern in 2008, as a Research Technician in the department of Molecular Genetics where I worked with a 2 member team in a fly lab, and extensively researched about fly genetics and learned molecular biology techniques such as QPCR, RNA silencing, cell culture and western blotting etc to good success across the research market.
Before joining UTSW, I received my Master's degree in Biotechnology from the University of Texas at Dallas in 2007. Later in 2012, I joined Dr. Mirzaei's lab and continued expansion of my research career and gained detailed knowledge on HPLC. Right now I am involved in 3 dimensional orthogonal protein separation using Chromatography.
I received my M.Sc. and Ph.D. in Molecular Biology of Cancer-Proteomics at the University of Leicester, United Kingdom. My Ph.D. dissertation title was plasma protein profiling for bladder cancer biomarker discovery using UPLC-HDMSE label-free quantitation.
In early 2013, I started my postdoc at the van Geest Proteomics Biomarker facility in Glenfield University Hospital in Leicester, UK where I was involved in a European Union Health Care Initiative called BIOSTAT-CHF, aimed at reducing the burden of heart failure through the development of personalized treatment.
Before joining the Hamid lab, I was engaged in mass-spectrometry based proteomics and biomarker discovery, including renal biomarker, cardiac biomarker, microbicide biomarker and drug-induced mitochondrial toxicity biomarker. Currently, I characterize the tau aggregates associate with disease by using mass spectrometry. I am working on characterizing and quantifying the tau aggregates associate with different diseases, such as Alzheimer's disease.